Pregnancy suppression by a structurally related antagonist for platelet activating factor, CV-6209, in mice.
The effects of CV-6209, a structurally related antagonist for platelet activating factor (PAF), on pregnancy were investigated in mice, so that the physiologic significance of PAF production by and secretion from preimplantation embryos could be elucidated. When it was repeatedly administered to pregnant mice during days 1-6 of pregnancy, CV-6209 prevented preimplantation thrombocytopenia and reduced the number of implantation sites dose-dependently, CV-6209 suppression of pregnancy was eliminated by concomitant administrations of PAF. When it was administered on various fractional days of pregnancy, CV-6209 suppressed pregnancy most effectively in mice treated during days 4-5 of pregnancy, the days of implantation. CV-6209 treatment exhibited no apparent effect on embryonic development. Implantation was suppressed when day 4 embryos from saline-treated donor mice were transferred in utero to CV-6209-treated recipient mice. Once implanted, however, their in utero growth was normal. The results indicate that PAF is prerequisite to pregnancy by promoting embryonic implantation.
Ando
M
M
Department of Obstetrics and Gynecology, Ehime University School of Medicine, Japan.
Suginami
H
H
Matsuura
S
S
D000818:Animals; D004305:Dose-Response Relationship, Drug; D010064:Embryo Implantation / Q000187:drug effects; D047108:Embryonic Development / Q000187:drug effects; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000502:physiology; D010976:Platelet Count / Q000187:drug effects; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000097:blood / Q000187:drug effects*; D011726:Pyridinium Compounds / Q000494:pharmacology*; D013921:Thrombocytopenia / Q000188:drug therapy; D013997:Time Factors
D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; C053321:CV 6209